164 related articles for article (PubMed ID: 15250050)
1. Strategies to improve dendritic cell-based immunotherapy against cancer.
Song SY; Kim HS
Yonsei Med J; 2004 Jun; 45 Suppl():48-52. PubMed ID: 15250050
[TBL] [Abstract][Full Text] [Related]
2. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells in cancer immunotherapy.
Gunzer M; Grabbe S
Crit Rev Immunol; 2001; 21(1-3):133-45. PubMed ID: 11642600
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based cancer immunotherapies.
Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
7. The use of dendritic cells in cancer immunotherapy.
Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
[TBL] [Abstract][Full Text] [Related]
8. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
9. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
Salem ML
Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
[TBL] [Abstract][Full Text] [Related]
10. RNA pulsed dendritic cells: an approach for cancer immunotherapy.
Garg NK; Dwivedi P; Prabha P; Tyagi RK
Vaccine; 2013 Feb; 31(8):1141-56. PubMed ID: 23306369
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell preparation for immunotherapeutic interventions.
Simon T; Fonteneau JF; Grégoire M
Immunotherapy; 2009 Mar; 1(2):289-302. PubMed ID: 20635946
[TBL] [Abstract][Full Text] [Related]
12. Potentiation strategies of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat.
Torabi-Rahvar M; Bozorgmehr M; Jeddi-Tehrani M; Zarnani AH
Drug Discov Today; 2011 Aug; 16(15-16):733-40. PubMed ID: 21558016
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
Sun K; Wang L; Zhang Y
Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
16. RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.
Tyagi RK; Mangal S; Garg N; Sharma PK
Expert Rev Anticancer Ther; 2009 Jan; 9(1):97-114. PubMed ID: 19105710
[TBL] [Abstract][Full Text] [Related]
17. Advances in dendritic cell-based vaccine of cancer.
Zhang X; Gordon JR; Xiang J
Cancer Biother Radiopharm; 2002 Dec; 17(6):601-19. PubMed ID: 12537664
[TBL] [Abstract][Full Text] [Related]
18. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
19. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
Xia D; Li F; Xiang J
Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
[TBL] [Abstract][Full Text] [Related]
20. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.
Foley R; Tozer R; Wan Y
Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
